Data obtained from the phagogram developed by PHAXIAM, the first phage sensitivity test with CE marking, showed a response rate of 98% on 105 clinical strains of S. aureus.
Lyon (France) and Cambridge (MA, US), October 9, 2023 – 10:05 p.m. CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), announces a very broad spectrum of activity of its anti-S phages. aureus (PP1493 and PP1815) against clinical bacterial strains.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email to the following address: [email protected]